The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity
Open accessAbstract
Whereas cancers grow within host tissues and evade host immunity through immune-editing and immunosuppression, tumours are rarely transmissible between individuals. Much like transplanted allogeneic organs, allogeneic tumours are reliably rejected by host T cells, even when the tumour and host share the same major histocompatibility complex alleles, the most potent determinants of transplant rejection. How such tumour-eradicating immunity is initiated remains unknown, although elucidating this process could provide the basis for inducing similar responses against naturally arising tumours. Here we find that allogeneic tumour rejection is initiated in mice by naturally occurring tumour-binding IgG antibodies, which enable dendritic cells (DCs) to internalize tumour antigens and subsequently activate tumour-reactive T cells. We exploited this mechanism to treat autologous and autochthonous tumours successfully. Either systemic administration of DCs loaded with allogeneic-IgG-coated tumour cells or intratumoral injection of allogeneic IgG in combination with DC stimuli induced potent T-cell-mediated antitumour immune responses, resulting in tumour eradication in mouse models of melanoma, pancreas, lung and breast cancer. Moreover, this strategy led to eradication of distant tumours and metastases, as well as the injected primary tumours. To assess the clinical relevance of these findings, we studied antibodies and cells from patients with lung cancer. T cells from these patients responded vigorously to autologous tumour antigens after culture with allogeneic-IgG-loaded DCs, recapitulating our findings in mice. These results reveal that tumour-binding allogeneic IgG can induce powerful antitumour immunity that can be exploited for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 715
p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi, T. (2000) · PubMed · Cited by 643
FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.019 · Cited by 590
B cells inhibit induction of T cell-dependent tumor immunity
Qin, Z., Richter, G., Schüler, T., Ibe, S., Cao, X., & Blankenstein, T. (1998) · Nature Medicine · doi:10.1038/nm0598-627 · Cited by 419
Haematopoietic cell transplantation as immunotherapy
Appelbaum, F. R. (2001) · Nature · doi:10.1038/35077251 · Cited by 411
DiLillo, D. J., Yanaba, K., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903009 · Cited by 359
Fc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
Reversing Lipopolysaccharide Toxicity by Ligating the Macrophage Fcγ Receptors
Gerber, J. S., & Mosser, D. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6861 · Cited by 263
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215640 · Cited by 232
Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P., Czerwinski, D. K., Nolan, G. P., & Levy, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002057107 · Cited by 167
Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Hamanaka, Y., Suehiro, Y., Fukui, M., Shikichi, K., Imai, K., & Hinoda, Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10801 · Cited by 165
Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
Li, Q., Lao, X., Pan, Q., Ning, N., Yet, J., Xu, Y., Li, S., & Chang, A. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0207 · Cited by 158
Willimsky, G., Czéh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., & Blankenstein, T. J. F. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072016 · Cited by 120
Immune Complex-Loaded Dendritic Cells Are Superior to Soluble Immune Complexes as Antitumor Vaccine
Schuurhuis, D. H., van Montfoort, N., Ioan‐Facsinay, A., Jiawan-Lalai, R., Camps, M. G. M., Nouta, J., Melief, C. J. M., Verbeek, J. S., & OSSENDORP, F. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4573 · Cited by 119
Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host
Tseng, W. W., Winer, D. A., Kenkel, J. A., Choi, O., Shain, A. H., Pollack, J. R., French, R., Lowy, A. M., & Engleman, E. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2384 · Cited by 90
Self-citationAntigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice
Manning, T. C., Rund, L. A., Gruber, M. M., Fallarino, F., Gajewski, T. F., & Kranz, D. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4665 · Cited by 51
Cited by
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
“Tumor-binding antibody therapy functions by enabling dendritic cell-mediated activation of T cells (Carmi et al., 2015).”
InfluentialSelf-citationB cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Kroeger, D. R., Milne, K., & Nelson, B. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2762 · Cited by 610
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Metadata
- Authors
- Carmi, Y., Spitzer, M. H., Linde, I. L., Burt, B. M., Prestwood, T. R., Perlman, N., Davidson, M. G., Kenkel, J. A., Segal, E., Pusapati, G. V., Bhattacharya, N., & Engleman, E. G.
- Venue
- Nature
- Published
- 2015-04-29
- Volume
- 521
- Issue
- 7550
- Pages
- 99-104
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051236462
- Cited by
- 259
- References
- 24
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.